News | October 05, 2009

Lexiscan Agent for MPI Meets the Standard

October 5, 2009 – A new analysis reaffirms that Lexiscan (regadenoson) Injection, the first selective A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress, requires infrequent use of the drug aminophylline to reverse its effect in the case of adverse events. The low use of aminophylline demonstrates that Lexiscan is similar to the current standard, Adenoscan (adenosine injection). Results were presented today at the 14th Annual Scientific Sessions of the American Society of Nuclear Cardiology (ASNC) in Minneapolis, Minn.

“This data further underscores that Lexiscan is not only as effective as Adenoscan in detection of perfusion defects by myocardial perfusion imaging but it also demonstrates that it is well-tolerated and has a side effect profile comparable to Adenoscan,” said Manuel Cerqueira, M.D., chairman of nuclear medicine in the imaging institute and staff cardiologist in the Heart and Vascular Institute at the Cleveland Clinic. “Based on the expanding body of evidence, Lexiscan proves to be an excellent choice for patients who cannot undergo adequate exercise stress.”

Aminophylline is a nonspecific, competitive adenosine receptor antagonist used to reverse the effects of pharmacologic stress agents like Lexiscan and Adenoscan. It is administered to ease symptoms in patients who experience adverse events after receiving a pharmacologic stress agent during an MPI test.

Using data from pivotal ADVANCE 1 and ADVANCE 2 double-blind, phase III trials of Lexiscan, researchers compared patient characteristics, side effects, and aminophylline treatment timing and dosage for 2,015 patients randomized to Lexiscan (n = 1,337) or Adenoscan (n = 678). Results showed that aminophylline was administered to 46 Lexiscan patients and 12 Adenoscan patients (3.4 and 1.8 percent respectively).

Although the use of aminophylline was slightly higher for patients randomized to Lexiscan than Adenoscan, no specific adverse event occurred significantly more often in Lexiscan than Adenoscan. The most common adverse events for which aminophylline was administered were angina pectoris, headache, electrocardiography (ECG) changes/ST segment depression, chest pain, and dyspnea (shortness of breath). Patients randomized to Lexiscan who received aminophylline were treated on average 4.5 minutes later than patients randomized to Adenoscan. Total aminophylline doses ranged from 72-300 mg for Lexiscan and from 25-240 mg for Adenoscan.

For Lexiscan stress MPI, there were no significant differences in age, body mass index, race, chronic obstructive pulmonary disease (COPD) history, diabetes history, serum creatinine levels, or creatinine clearance between those receiving aminophylline and those not receiving aminophylline. Patients receiving aminophylline were more likely to have a history of unstable angina, be of female gender, and have enrolled in a clinical trial conducted outside the United States.

For more information: www.lexiscan.com

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init